Fasting glucose improved within weeks and my HbA1c barely moved for three months, which I now understand and did not at the time.
Because it is glucose-dependent, this class carries a low intrinsic hypoglycaemia risk on its own — the risk arrives when it is combined with insulin or a sulfonylurea, which usually need reducing.
What I am trying to establish is why A1C lags the way it does, and what to look at in the meantime if you want to know sooner.
Practical detail welcome, however dull — the duller the better.
KarenAZ_mom said:Fasting glucose improved within weeks and my HbA1c barely moved for three months, which I now understand and did not at the time.
Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 42% to 22%. Target is <36%, with <30% being ideal.
Why this matters more than average glucose: large glucose swings cause oxidative stress, endothelial damage, and promote advanced glycation end-products (AGEs). A flat glucose line at 95 mg/dL is metabolically healthier than oscillating between 60 and 160, even if the average is the same.
LarryQC_SD said:Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 42% to 22%.
Patient selection optimization for glycaemic control: emerging predictive biomarkers for GLP-1 agonist response include:
| Biomarker | Association | Evidence Level |
|---|---|---|
| Baseline BMI | Higher BMI → greater absolute weight loss | Strong |
| Fasting insulin | Higher insulin → better response | Moderate |
| GLP1R gene variants | rs6923761 → variable response | Preliminary |
| Baseline hsCRP | Higher CRP → greater CV benefit | Moderate |
| Early weight loss (4 wk) | ≥3% at 4 wks → strong predictor of ≥10% at 68 wks | Strong |
The 4-week early responder criterion is the most clinically actionable: if you haven't lost ≥3% by week 4 at a therapeutic dose, discuss optimization strategies with your provider.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsKarenAZ_mom said:Fasting glucose improved within weeks and my HbA1c barely moved for three months, which I now understand and did not at the time.
Same experience, arrived at from the opposite direction. The detail I would add is minor and it is already implied above.
From the other side of the consultation, briefly.
Complete metabolic panel trending on glycaemic control — sharing because comprehensive data helps everyone:
| Test | Baseline | Month 3 | Month 6 | Month 12 |
|---|---|---|---|---|
| Glucose (fasting) | 129 | 103 | 93 | 87 |
| Insulin (fasting) | 25 | 17 | 9 | 7 |
| HOMA-IR | 5.5 | 3.0 | 2.1 | 1.3 |
| Uric Acid | 7.7 | 6.9 | 6.0 | 5.0 |
The insulin resistance improvement (HOMA-IR) is what my endo focuses on most. Going from 5.5 to near 1.0 is a metabolic transformation.